Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The VEGF165b "ICE-o-form" puts a chill on the VEGF story.

Literature DB >> 21778432

The VEGF165b "ICE-o-form" puts a chill on the VEGF story.

Ayotunde O Dokun, Brian H Annex.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2011 PMID： 21778432 PMCID： PMC3196354 DOI： 10.1161/CIRCRESAHA.111.249953

Source DB: PubMed Journal: Circ Res ISSN： 0009-7330 Impact factor: 17.367

× No keyword cloud information.

16 in total

1. Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease.

Authors: Ferdinando Carlo Sasso; Daniele Torella; Ornella Carbonara; Georgina M Ellison; Michele Torella; Michelangelo Scardone; Claudio Marra; Rodolfo Nasti; Raffaele Marfella; Domenico Cozzolino; Ciro Indolfi; Maurizio Cotrufo; Roberto Torella; Teresa Salvatore
Journal: J Am Coll Cardiol Date: 2005-09-06 Impact factor: 24.094

Review 2. Targeting VEGF-A to treat cancer and age-related macular degeneration.

Authors: Napoleone Ferrara; Robert D Mass; Claudio Campa; Robert Kim
Journal: Annu Rev Med Date: 2007 Impact factor: 13.739

3. Induction of podocyte VEGF164 overexpression at different stages of development causes congenital nephrosis or steroid-resistant nephrotic syndrome.

Authors: Delma Veron; Kimberly Reidy; Arnaud Marlier; Claudia Bertuccio; Guillermo Villegas; Juan Jimenez; Michael Kashgarian; Alda Tufro
Journal: Am J Pathol Date: 2010-09-09 Impact factor: 4.307

4. Neutralization of vascular endothelial growth factor antiangiogenic isoforms is more effective than treatment with proangiogenic isoforms in stimulating vascular development and follicle progression in the perinatal rat ovary.

Authors: Robin A Artac; Renee M McFee; Robyn A Longfellow Smith; Michelle M Baltes-Breitwisch; Debra T Clopton; Andrea S Cupp
Journal: Biol Reprod Date: 2009-07-15 Impact factor: 4.285

5. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1.

Authors: Surovi Hazarika; Ayotunde O Dokun; Yongjun Li; Aleksander S Popel; Christopher D Kontos; Brian H Annex
Journal: Circ Res Date: 2007-09-06 Impact factor: 17.367

6. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.

Authors: D R Senger; S J Galli; A M Dvorak; C A Perruzzi; V S Harvey; H F Dvorak
Journal: Science Date: 1983-02-25 Impact factor: 47.728

7. Expression of vascular endothelial growth factor, stromal cell-derived factor-1, and CXCR4 in human limb muscle with acute and chronic ischemia.

Authors: Vincent van Weel; Leonard Seghers; Margreet R de Vries; Esther J Kuiper; Reinier O Schlingemann; Ingeborg M Bajema; Jan H N Lindeman; Pien M Delis-van Diemen; Victor W M van Hinsbergh; J Hajo van Bockel; Paul H A Quax
Journal: Arterioscler Thromb Vasc Biol Date: 2007-03-15 Impact factor: 8.311

8. Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease.

Authors: Clarence M Findley; Robert G Mitchell; Brian D Duscha; Brian H Annex; Christopher D Kontos
Journal: J Am Coll Cardiol Date: 2008-07-29 Impact factor: 24.094

Review 9. Vascular endothelial growth factor: basic science and clinical progress.

Authors: Napoleone Ferrara
Journal: Endocr Rev Date: 2004-08 Impact factor: 19.871

10. The anti-angiogenic isoforms of VEGF in health and disease.

Authors: Yan Qiu; Coralie Hoareau-Aveilla; Sebastian Oltean; Steven J Harper; David O Bates
Journal: Biochem Soc Trans Date: 2009-12 Impact factor: 5.407

10 in total

1. Alteration in angiogenic and anti-angiogenic forms of vascular endothelial growth factor-A in skeletal muscle of patients with intermittent claudication following exercise training.

Authors: W Schuyler Jones; Brian D Duscha; Jennifer L Robbins; Natasha N Duggan; Judith G Regensteiner; William E Kraus; William R Hiatt; Ayotunde O Dokun; Brian H Annex
Journal: Vasc Med Date: 2012-03-08 Impact factor: 3.239

Review 2. Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning.

Authors: Prakash Vempati; Aleksander S Popel; Feilim Mac Gabhann
Journal: Cytokine Growth Factor Rev Date: 2013-11-27 Impact factor: 7.638

3. Predicting the effects of anti-angiogenic agents targeting specific VEGF isoforms.

Authors: Stacey D Finley; Aleksander S Popel
Journal: AAPS J Date: 2012-05-01 Impact factor: 4.009

4. Effect of tumor microenvironment on tumor VEGF during anti-VEGF treatment: systems biology predictions.

Authors: Stacey D Finley; Aleksander S Popel
Journal: J Natl Cancer Inst Date: 2013-05-13 Impact factor: 13.506

5. Compartment model predicts VEGF secretion and investigates the effects of VEGF trap in tumor-bearing mice.

Authors: Stacey D Finley; Manjima Dhar; Aleksander S Popel
Journal: Front Oncol Date: 2013-07-30 Impact factor: 6.244

6. An antiangiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease.

Authors: Ryosuke Kikuchi; Kazuto Nakamura; Susan MacLauchlan; Doan Thi-Minh Ngo; Ippei Shimizu; Jose Javier Fuster; Yasufumi Katanasaka; Sumiko Yoshida; Yan Qiu; Terry P Yamaguchi; Tadashi Matsushita; Toyoaki Murohara; Noyan Gokce; David O Bates; Naomi M Hamburg; Kenneth Walsh
Journal: Nat Med Date: 2014-11-02 Impact factor: 53.440